Development and Validation of Stability Indicating RP-LC Method for Estimation of Ranolazine in Bulk and Its Pharmaceutical Formulations ()
Ganji Ramanaiah,
D. Ramachandran,
G. Srinivas,
Jayapal Gowardhane,
Purnachanda Rao,
Srilakshmi. V
Department of Chemistry, Acharya Nagarjuna University Nuzivid Campus, Andhra Pradesh, India.
DOI: 10.4236/ajac.2012.35050
PDF
HTML
5,385
Downloads
9,697
Views
Citations
Abstract
An isocratic reverse phase liquid chromatography (RP-LC) method has been developed and subsequently validated for the determination of Ranolazine in Bulk and its pharmaceutical formulation. Separation was achieved with a X-terra RP-18 ((Make: Waters Corporation; 150 mm × 4.6 mm I.D.; particle size 5 μm)) Column and Sodium di-hydrogen phosphate monohydrate buffer with Tri ethyl amine (pH adjusted to 5.0 with diluted orthophosphoric acid): Acetonitrile (600:400) v/v as eluent at a flow rate of 1.0 mL/min. UV detection was performed at 225 nm. The method is simple, rapid, and selective. The described method of Ranolazine is linear over a range of 11.98 μg/mL to 37.92 μg/mL. The method precision for the determination of assay was below 1.0%RSD. The percentage recoveries of active pharmaceutical ingredient (API) from dosage forms ranged from 99.1% to 100.9%. The results showed that the proposed method is suitable for the precise, accurate and rapid determination of Ranolazine in bulk, its capsule dosage forms.
Share and Cite:
G. Ramanaiah, D. Ramachandran, G. Srinivas, J. Gowardhane, P. Rao and S. V, "Development and Validation of Stability Indicating RP-LC Method for Estimation of Ranolazine in Bulk and Its Pharmaceutical Formulations,"
American Journal of Analytical Chemistry, Vol. 3 No. 5, 2012, pp. 378-384. doi:
10.4236/ajac.2012.35050.
Conflicts of Interest
The authors declare no conflicts of interest.
References
|
[1]
|
www.druginfo.nlm.nih.gov
|
|
[2]
|
www.rxlist.com
|
|
[3]
|
C. Greenaway, N. Ratnaraj, J. W. Sander and P. N. Patsalos, “A High-Performance Liquid Chromatography Assay to Monitor the New Antiepileptic Drug Lacosamide in Patients with Epi-lepsy,” Therapeutic Drug Monitoring, Vol. 32, No. 4, 2010, pp. 448.doi.org/10.1097/FTD.0b013e3181dcc5fb
|
|
[4]
|
L. R. Snyder, J. J. Kirkland and J. L. Glajch, “Practical HPLC Method Development,” 2nd Edition, Wiley-Inter-science, New York, 1997.
|
|
[5]
|
United States Pharmacopeia, USP 34-NF 29, 2011.
|
|
[6]
|
ICH Guidelines on Validation of Analytical Procedure: Text and Methodology Q 2 (R1), 2011.
|